Reported about 20 hours ago
Sarepta Therapeutics announced that a patient died from acute liver injury while undergoing its gene therapy, Elevidys, for muscular dystrophy, leading to a significant drop in the company's share price. This incident marks the first recorded death associated with the therapy, which has been administered to over 800 patients. Although the company noted the patient's recent infection could have contributed to the liver issues, it plans to update the drug's prescribing information accordingly.
Source: YAHOO